CA2874028C - Polytherapie impliquant des anticorps diriges contre la claudine 18,2 pour le traitement du cancer - Google Patents

Polytherapie impliquant des anticorps diriges contre la claudine 18,2 pour le traitement du cancer

Info

Publication number
CA2874028C
CA2874028C CA2874028A CA2874028A CA2874028C CA 2874028 C CA2874028 C CA 2874028C CA 2874028 A CA2874028 A CA 2874028A CA 2874028 A CA2874028 A CA 2874028A CA 2874028 C CA2874028 C CA 2874028C
Authority
CA
Canada
Prior art keywords
seq
cells
antibody
positions
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2874028A
Other languages
English (en)
Other versions
CA2874028A1 (fr
Inventor
Ugur Sahin
Ozlem Tureci
Rita Mitnacht-Kraus
Stefan Denis Jacobs
Magdalena Jadwiga Utsch
Cornelia Adriana Maria Heinz
Christiane Regina Stadler
Original Assignee
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/002211 external-priority patent/WO2013174404A1/fr
Application filed by TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH, Astellas Pharma Inc filed Critical TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Publication of CA2874028A1 publication Critical patent/CA2874028A1/fr
Application granted granted Critical
Publication of CA2874028C publication Critical patent/CA2874028C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne une polythérapie qui permet de traiter et/ou de prévenir efficacement des maladies associées à des cellules exprimant CLD18,2; notamment des cancers tels que le cancer gastrique, le cancer de l'sophage, le cancer du pancréas, le cancer des poumons, le cancer des ovaires, le cancer du côlon, le cancer hépatique, le cancer de la tête et du cou et le cancer de la vésicule biliaire et leurs métastases.
CA2874028A 2012-05-23 2013-05-21 Polytherapie impliquant des anticorps diriges contre la claudine 18,2 pour le traitement du cancer Active CA2874028C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2012/002211 2012-05-23
PCT/EP2012/002211 WO2013174404A1 (fr) 2012-05-23 2012-05-23 Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
PCT/EP2013/001503 WO2013174509A1 (fr) 2012-05-23 2013-05-21 Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer

Publications (2)

Publication Number Publication Date
CA2874028A1 CA2874028A1 (fr) 2013-11-28
CA2874028C true CA2874028C (fr) 2026-02-24

Family

ID=

Similar Documents

Publication Publication Date Title
US12059464B2 (en) Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
AU2018201391B2 (en) Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
EP3254695B1 (fr) Thérapie d'association comprenant des anticorps contre la claudine 18.2 pour le traitement du cancer
EP2852409B1 (fr) Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 pour le traitement du cancer
CA2874028C (fr) Polytherapie impliquant des anticorps diriges contre la claudine 18,2 pour le traitement du cancer
HK40110865A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40126719A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40087661A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40049154A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40049154B (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40039705A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK40039705B (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK1208152B (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer